CrushSCI.com
158.9Average days
133Median days
49Fastest days
347Longest days
1442025 publications

Paper Review Records

All Paper Review Records

28 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

320 days

Regulatory T‐Cell Dynamics During and After Direct Acting Antivirals in Cirrhotic HCV Genotype 4 Patients

Authors
Riham Soliman; Douaa Sayed; Ayman A. Hassan; Nabiel N. H. Mikhail; Ahmed Nabil; Nada El‐Domiaty; Gamal ShihaShow moreShow less
Affiliations
1. Egyptian Liver Research Institute and Hospital (ELRIAH) El Mansoura Egypt; 2. Technical Institute of Nusring Sherbin Egypt; 3. Clinical Pathology Department, Faculty of Medicine Suez University Suez Egypt; 4. Medical Laboratories Department Higher Technological Institute of Applied Health Sciences Mansoura Egypt; 5. Biostatistics and Cancer Epidemiology Department, South Egypt Cancer Institute Assiut University Assiut Egypt; 6. Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS) Beni‐Suef University Beni‐Suef Egypt; 7. Endemic Medicine Department, Faculty of Medicine Helwan University Cairo Egypt; 8. Gastroenterology and Hepatology Unit, Internal Medicine Department, Faculty of Medicine Mansoura University Mansoura EgyptShow moreShow less
Source PDF DOI Publisher page
159 days

Triple Elimination of HIV, Syphilis and HBV Mother‐To‐Child Transmission in Africa: From a WHO Initiative to a Respondent‐Level Reality

Authors
Erwan Vo‐Quang; Gibril Ndow; Lindsey Hiebert; Neil Gupta; Jana Manning; John Ward; Maud LemoineShow moreShow less
Affiliations
1. MRC Unit The Gambia at London School of Hygiene & Tropical Medicine Banjul The Gambia; 2. Department of Gastroenterology and Digestive Oncology Georges Pompidou European Hospital Paris France; 3. Coalition for Global Hepatitis Elimination, Task Force for Global Health Decatur Georgia USA; 4. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta Georgia USA; 5. Section of Hepatology, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction Imperial College London London UKShow moreShow less
Source PDF DOI Publisher page
213 days

Increasing HCV Diagnosis and Treatment Uptake Among Community‐Recruited People Who Inject Drugs in Athens, Greece, During the Transition to Unrestricted Access to Direct‐Acting Antivirals

Authors
Sotirios Roussos; Georgios Papatheodoridis; Theodoros Angelopoulos; Evangelos Cholongitas; Nikolaos Papadopoulos; Spyridon Savvanis; Athina Chounta; Fani Pliarchopoulou; Panagiota Ioannidou; Melanie Deutsch; Maria‐Vasiliki Papageorgiou; Spilios Manolakopoulos; Vasileios Sevastianos; Andreas Kapatais; Ioannis Vlachogiannakos; Maria Mela; Ioannis Elefsiniotis; Spyridon Vrakas; Dimitrios S. Karagiannakis; Savvas Chaikalis; Dimitrios Paraskevis; Mina Psichogiou; George Kalamitsis; Angelos Hatzakis; Vana SypsaShow moreShow less
Affiliations
1. Department of Hygiene Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens Athens Greece; 2. 1st Department of Gastroenterology General Hospital of Athens “Laiko”, Medical School, National and Kapodistrian University of Athens Athens Greece; 3. Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases Athens Greece; 4. 1st Department of Internal Medicine General Hospital of Athens “Laiko”, Medical School, National and Kapodistrian University of Athens Athens Greece; 5. 1st Department of Internal Medicine 417 Army Share Fund Hospital of Athens Athens Greece; 6. Department of Internal Medicine General Hospital of Athens “Elpis” Athens Greece; 7. 4th Department of Internal Medicine Attikon University General Hospital, Medical School, National and Kapodistrian University of Athens Athens Greece; 8. 2nd Academic Department of Internal Medicine Hippokration General Hospital, Medical School, National and Kapodistrian University of Athens Athens Greece; 9. Liver‐Gastroenterology Unit, 2nd Academic Department of Internal Medicine Hippokration General Hospital, Medical School, National and Kapodistrian University of Athens Athens Greece; 10. 3rd Department of Internal Medicine and Liver Unit “Evangelismos” General Hospital Athens Greece; 11. 1st Department of Internal Medicine Western Attica General Hospital “Agia Varvara” Athens Greece; 12. Gastroenterology Department “Evangelismos” General Hospital Athens Greece; 13. Academic Department of Internal Medicine ‐ Hepatogastroenterology Unit General and Oncology Hospital of Kifisia “Agioi Anargyroi”, Faculty of Nursing, National and Kapodistrian University of Athens Athens Greece; 14. Department of Gastroenterology Tzaneion General Hospital of Piraeus Piraeus Greece; 15. Hellenic Liver Patient Association “Prometheus” Athens GreeceShow moreShow less
Source PDF DOI Publisher page
134 days

The Safety, Pharmacokinetics, and Antiviral Activity of ABI ‐4334, A Novel Next‐Generation Hepatitis B Capsid Assembly Modulator

Authors
Edward J. Gane; Christian Schwabe; Nelli Ghicavii; Cristina Ticot; Katie Zomorodi; Steven J. Knox; Kathryn M. Kitrinos; Ran Yan; Jieming Liu; Grace Wang; Anuj Gaggar; Alina JucovShow moreShow less
Affiliations
1. University of Auckland Auckland New Zealand; 2. New Zealand Clinical Research Auckland New Zealand; 3. ARENSIA Exploratory Medicine GmbH, Republican Clinical Hospital Chișinău Republic of Moldova; 4. Assembly Biosciences, Inc. South San Francisco California USA; 5. Department of Gastroenterology Nicolae Testemițanu State University of Medicine and Pharmacy Chișinău Republic of MoldovaShow moreShow less
Source PDF DOI Publisher page
190 days

Hepatitis B and D: Interferon‐Based Therapy—For Clinical Trials or Standard of Care—Back to the Future?

Authors
Zillah Cargill; Harry L. A. Janssen; Tarik Asselah; Kosh AgarwalShow moreShow less
Affiliations
1. Institute of Liver Studies, King's College Hospital London UK; 2. Department of Gastroenterology and Hepatology, Erasmus MC University Hospital Rotterdam Rotterdam the Netherlands; 3. Toronto General Hospital University of Toronto Toronto Ontario Canada; 4. Hôpital Beaujon, AP‐HP Assistance Publique—Hopitaux de Paris, INSERM UMR1149, Université de Paris‐Cité Paris FranceShow moreShow less
Source PDF DOI Publisher page
130 days

Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 ( MINMON ) Clinical Trial

Authors
Win Min Han; Sunil Solomon; Sandra Wagner‐Cardoso; Jiani Li; Aiyappa Parvangada; Mark Sulkowski; Susanna Naggie; Ross Martin; Hongmei Mo; Evguenia Maiorova; David Wyles; the ACTG A5360 study teamShow moreShow less
Affiliations
1. The HIV Netherlands Australia Thailand Research Collaboration (HIVNAT), Thai Red Cross AIDS and Infectious Diseases Research Centre Bangkok Thailand; 2. Kirby Institute UNSW Sydney Sydney Australia; 3. Johns Hopkins University School of Medicine Baltimore Maryland USA; 4. Instituto Nacional de Infectologia Evandro Chagas Fundação Oswaldo Cruz Rio de Janeiro Brazil; 5. Gilead Sciences, Inc. Foster City California USA; 6. Duke University Medical Center Durham North Carolina USAShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does JOURNAL OF VIRAL HEPATITIS take to review a manuscript?

As of 2026-11-17, CrushSCI has 28 complete review records for JOURNAL OF VIRAL HEPATITIS. The fastest paper went from submission to acceptance in 49 days (Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients, received 2026-05-20, accepted 2026-07-08); the slowest took 347 days. The average is 158.9 days and the median is 133 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.